Glenmark Recollects Over 25 Products
As per a PTI report citing the USFDA, Mumbai-based mostly Glenmark is recalling greater than 25 products in the US market on account of deviations from Present Good Manufacturing Follow (CGMP) requirements.
New Jersey-based mostly Glenmark Prescription drugs Inc is withdrawing affected plenty of drugs together with Propafenone Hydrochloride prolonged-launch capsules and Solifenacin Succinate Tablets.
The corporate can be recalling different products reminiscent of Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets, and Rufinamide Tablets. This Class II recall was initiated on March 13, 2025.
In response to the USFDA, a Class II recall is issued when using or publicity to a violative product could trigger non permanent or medically reversible well being results, with a low chance of significant penalties.
Sun Pharma Recollects Gabapentin Capsules
A US-based subsidiary of Sun Pharma is recalling roughly 13,700 bottles of Gabapentin capsules, that are used to deal with and forestall seizures in individuals with epilepsy.
New Jersey-based mostly Sun Pharmaceutical Industries Inc is conducting the recall on account of cross-contamination considerations, in keeping with the USFDA. The Class III recall was initiated on March 4, 2025.
Zydus Recollects Chlorpromazine Tablets
Zydus Prescription drugs (USA) Inc is recalling 3,144 bottles of Chlorpromazine Hydrochloride Tablets, USP 10 mg, a medicine prescribed for psychological well being circumstances reminiscent of schizophrenia and bipolar dysfunction.
The recall was initiated on account of CGMP deviations, the USFDA mentioned. The affected batch was discovered to include “N-Nitroso-Desmethyl Chlorpromazine impurity above the really helpful interim restrict.” The corporate started the Class II recall on April 3, 2025.
Source link
#Glenmark #Sun #Pharma #Zydus #recall #products #compliance #issues #CNBC #TV18
